Hrycek Eugeniusz, Walawska-Hrycek Anna, Milewski Krzysztof, Nowakowski Przemysław, Buszman Piotr, Żurakowski Aleksander
American Heart of Poland, Topolowa 16, 32-500 Chrzanów, Poland.
Department of Cardiology, Faculty of Medical Sciences, Andrzej Frycz Modrzewski Kraków University, 30-705 Kraków, Poland.
Vaccines (Basel). 2024 Aug 29;12(9):983. doi: 10.3390/vaccines12090983.
This multi-site retrospective analysis with a control group was devised to evaluate the impact of prophylactic SARS-CoV-2 vaccination the on outcomes of myocardial infarction (MI) patients with confirmed COVID-19. An overall of 129 subjects who had been diagnosed with COVID-19 and MI were included in the analysis and were divided into the study group (44 vaccinated patients) and the control group (85 non-vaccinated comparable patients). The primary outcome measure was defined as the time until in-hospital death, while the secondary outcome measure was defined as the time until death outside the hospital setting. According to in-hospital mortality analysis, 1 (2.27%) subject died in the study group, whereas a total of 19 (22.4%) subjects died among the controls (OR = 0.08; CI: 0.001-0.553; = 0.023). The impact of vaccination on the in-hospital outcomes of patients treated for COVID-19 and MI was further confirmed using Cox regression analysis (HR: 0.1 CI: 0.01-0.77; = 0.026). The observed difference was the absence of respiratory failure requiring mechanical ventilation in the study group, whereas it was observed in 14 (16.47%) patients in the control group. During out-of-hospital observation, there were no observed differences in mortality (OR: 1.56; 95% CI: 0.21-11.52; = 0.66). The complete prophylactic SARS-CoV-2 vaccination course demonstrates a protective role in patients undergoing treatment for MI with confirmed COVID-19 during in-hospital observation.
本项设有对照组的多中心回顾性分析旨在评估预防性接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗对确诊新型冠状病毒肺炎（COVID-19）的心肌梗死（MI）患者预后的影响。共有129例被诊断为COVID-19和MI的受试者纳入分析，并分为研究组（44例接种疫苗的患者）和对照组（85例未接种疫苗的可比患者）。主要结局指标定义为至院内死亡的时间，次要结局指标定义为至院外死亡的时间。根据院内死亡率分析，研究组有1例（2.27%）受试者死亡，而对照组共有19例（22.4%）受试者死亡（比值比[OR]=0.08；置信区间[CI]：0.001-0.553；P=0.023）。使用Cox回归分析进一步证实了接种疫苗对接受COVID-19和MI治疗患者院内结局的影响（风险比[HR]：0.1；CI：0.01-0.77；P=0.026）。观察到的差异是研究组没有出现需要机械通气的呼吸衰竭，而对照组有14例（16.47%）患者出现。在院外观察期间，未观察到死亡率的差异（OR：1.56；95%CI：0.21-11.52；P=0.66）。完整的预防性SARS-CoV-2疫苗接种疗程在确诊COVID-19的MI治疗患者的院内观察期间显示出保护作用。
